NCT07306949

Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers

A Multicenter, Open-Label, Single Arm, Post-Marketing Clinical Study to Evaluate the Therapeutic Effects of Acoramidis Hydrochlorideon Cardiac Biomarkers and Current Clinical Features in Patients With Transthyretin-type Cardiac Amyloidosis: The CARE ATTR Study

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Alexion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.

Conditions

• Transthyretin-type Cardiac Amyloidosis

Interventions

Type	Name	Description
DRUG	Acoramidis	Participants will receive acoramidis tablets orally.

Timeline

• Start date: 2025-10-01
• Primary completion: 2028-03-31
• Completion: 2028-03-31
• First posted: 2025-12-29
• Last updated: 2026-01-07

Locations

16 sites across 1 country: Japan